MoriMGanGBin MahmoodSU, et al. Variations in anticoagulation practice following bioprosthetic aortic and mitral valve replacement and repair. J Am Coll Cardiol2020; 76: 2412–2413.
2.
OttoCMNishimuraRABonowRO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation2021; 143: e72–e227.
3.
PrazFBorgerMALanzJ, et al. 2025 ESC/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2025; 46: 4635–4736.
4.
HuangYSchaffHVSwarnaKS, et al. Benefit of anticoagulation early after surgical aortic valve replacement using bioprosthetic valves. Mayo Clin Proc2023; 98: 1797–1808.
5.
IzumiCAmanoMYoshikawaY, et al. Efficacy and safety of edoxaban in anticoagulant therapy early after surgical bioprosthetic valve replacement: a randomized clinical trial. Circ Cardiovasc Interv2025; 18: e015108.
6.
AlkhalilMEdwardsRPuriR, et al. Aspirin versus dual antiplatelet therapy in patients undergoing trans-catheter aortic valve implantation, updated meta-analysis. Cardiovasc Drugs Ther2022; 36: 279–283.
7.
DangasGDTijssenJGPWöhrleJ, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med2020; 382: 120–129.
8.
BendandiFPalmeriniTDe MarcoF, et al. Dual vs single antiplatelet therapy after transcatheter aortic valve replacement for bioprosthetic valve failure. JACC Cardiovasc Interv2025; 18: 2728–2739.
9.
ZormanMJVibhishananJDangasK, et al. Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother2025; 11: 251–263.
10.
GbreelMIElkasabyMHHassanM, et al. Optimizing antithrombotic therapy following mitral valve repair: a comprehensive network meta-analysis. BMC Cardiovasc Disord2025; 25: 628.
11.
ZhangJYangYJiaL, et al. Anticoagulation therapy and clinical outcomes following transcatheter mitral valve repair for patients with mitral regurgitation: a meta-analysis. Clin Cardiol2023; 46: 598–606.
12.
PaparellaDDi MauroMBitton WormsK, et al. Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair. J Thorac Cardiovasc Surg2016; 151: 1302–1308.
13.
StrangeJESindet-PedersenCStaerkL, et al. All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. Eur Heart J Cardiovasc Pharmacother2021; 7: f93–f100.
14.
PaparellaDBelley-CoteEPDi MauroM, et al. Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the Left Atrial Appendage Occlusion Study (LAAOS) III trial. J Thorac Cardiovasc Surg. Epub ahead of print 8 September 2025. DOI: 10.1016/j.jtcvs.2025.08.046.
15.
GuimarãesPOPokorneySDLopesRD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol2019; 42: 568–571.
16.
De CaterinaRRendaGCarnicelliAP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol2017; 69: 1372–1382.
17.
MentiasASaadMMichaelM, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc2022; 11: e026666.
18.
Al SaidSKaierKNuryE, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis. Cochrane Database Syst Rev2025; 2: CD013745.
